PGT and Embryo Screening in Surrogacy: What Intended Parents Should Know

Most intended parents arrive at the topic of embryo screening through a very practical question: once we have embryos, how do we decide which one to transfer to the surrogate? That decision is where preimplantation genetic testing, usually shortened to PGT, comes into the conversation. For families building through gestational surrogacy, PGT is one of the most discussed - and most misunderstood - steps in the entire medical process.

This guide is written for intended parents who are researching how PGT and embryo screening fit into a U.S. surrogacy journey. It explains, in plain language, what the different types of PGT are, how the screening process actually works from biopsy to result, what is and is not normally included, the factors that shape whether screening is worth considering for your specific situation, how U.S. state and jurisdiction differences affect the broader journey, and what a realistic timeline looks like. It also connects you to the rest of our educational cluster, including our guide to how IVF and surrogacy work, our surrogacy cost breakdown, and our surrogacy timeline.

One point is repeated on purpose because it protects you: this article is informational only. It describes common terminology, widely used laboratory steps, and typical journey structures across many U.S. fertility clinics, surrogacy agencies, and reproductive attorneys. It is not medical, genetic, or legal advice, and it is not a quote, not an offer, and not a guarantee of any specific outcome, test result, timeline, or success. Every intended parent, egg donor, surrogate, clinic, and jurisdiction is evaluated individually. No statistic or range in this article should be read as a promise about your family-building result, and nothing here is a substitute for licensed medical and legal counsel in your state.

If you are new to the overall concept, our overview of how gestational surrogacy works explains the full journey your screening decision supports, and our requirements and eligibility guide explains who can participate.

How PGT and Embryo Screening Work: The Short Version

For readers who want the essentials first, here is how most PGT journeys move from egg retrieval to a screened embryo ready for the surrogate:

Create embryos through IVF - eggs (from the intended mother or an egg donor) are fertilized with sperm, most often via ICSI, and cultured in the lab toward the blastocyst stage. Our IVF and surrogacy explainer walks through this step in detail.
Grow to blastocyst - embryos are typically grown to day five or six, when a small number of cells have differentiated into the trophectoderm (the tissue that becomes the placenta) and the inner cell mass (the tissue that becomes the baby).
Biopsy a few cells - a trained embryologist removes a small sample of trophectoderm cells from each blastocyst. The inner cell mass is not biopsied, which is why the test is described as sampling placental-lineage cells.
Vitrify (freeze) the embryos - because results take time, the biopsied blastocysts are normally frozen by vitrification while the biopsy samples are sent to an accredited genetics laboratory.
Run the genetic test - the lab analyzes the samples for the specific question being asked (chromosome count, a single-gene condition, or a structural rearrangement), depending on the PGT type selected.
Receive a report - the genetics lab returns a per-embryo result, typically classifying each embryo as euploid (expected normal chromosome count), mosaic (mixed), or aneuploid (an abnormal number of chromosomes), or as affected, carrier, or unaffected for single-gene questions.
Select the embryo for transfer - you and your clinic review the report and choose which screened embryo to thaw and transfer to your surrogate, usually prioritizing the highest-quality euploid embryo available.
Prepare and transfer - the surrogate follows her prepared cycle, and the selected embryo is transferred, after which the standard pregnancy confirmation steps begin. Our matching guide and surrogate application guide cover the surrounding journey.

What "PGT" Actually Means: The Three Main Types

The single acronym "PGT" covers several distinct tests. Understanding the difference matters, because the right test for one family is the wrong test for another.

PGT-A (aneuploidy screening) - formerly known as PGS, this checks whether each embryo has the expected number of chromosomes. Aneuploidy (an extra or missing chromosome) is a leading reason embryos fail to implant or pregnancies end in early loss. PGT-A is the most commonly discussed form for intended parents using gestational surrogacy.
PGT-M (monogenic or single-gene testing) - used when one or both genetic parents are known carriers of, or affected by, a specific inherited single-gene condition. The lab builds a custom probe for that condition and reports whether each embryo is affected, a carrier, or unaffected. This is a custom process that often takes longer to set up than PGT-A.
PGT-SR (structural rearrangement testing) - used when a genetic parent has a balanced chromosomal translocation or inversion. The test helps identify embryos with a balanced or normal arrangement versus those with unbalanced arrangements that are unlikely to result in a healthy pregnancy.

There is also related testing such as expanded carrier screening of the parents and, in some cases, embryo polar-body or other approaches, but PGT-A, PGT-M, and PGT-SR are the three core categories most intended parents encounter. Which test - if any - is appropriate depends entirely on your family's medical history, the egg and sperm sources, your clinic's protocols, and your reproductive attorney's and physician's guidance.

What Is Included in PGT - and What Is Not

A frequent source of confusion is what the word "PGT" actually covers. The table below separates what the testing step normally includes from what it does not.

Typically included in the PGT step	Not included in the PGT step
Trophectoderm biopsy of blastocyst-stage embryos by an embryology team	The IVF stimulation, egg retrieval, and fertilization that create the embryos
Vitrification (freezing) of biopsied embryos while awaiting results	Genetic carrier screening of the intended parents or donors (a separate pre-test)
Shipment of biopsy samples to an accredited genetics laboratory	The surrogate's medical preparation, monitoring, and the embryo transfer procedure
Chromosome or single-gene analysis per the selected PGT type	Any interpretation of results by your own physician or genetic counselor (often billed separately or included in consult)
A per-embryo report classifying each blastocyst	Storage fees for frozen embryos, which are usually a recurring separate line item
Re-biopsy in limited cases where a sample is inconclusive (lab-dependent)	Treatment of any underlying infertility or medical condition of the genetic parents

The key takeaway: PGT is a laboratory analysis layered on top of an IVF cycle. It does not replace the IVF, the egg donor process if one is used, the surrogate compensation and legal work, or the transfer itself. All of those remain separate components of the fuller journey documented in our cost and financing overview.

Factors That Influence Whether PGT Makes Sense for Your Journey

PGT is a tool, not a requirement, and whether it is worth discussing depends on several factors. None of these factors determines an outcome; they shape the conversation you have with your clinic and attorney.

Maternal age of the egg source - the chance of chromosomal aneuploidy in an embryo rises with the age of the person providing the eggs. This is one of the most commonly cited reasons families consider PGT-A, but it is a probability discussion, not a guarantee about any single embryo.
Known carrier or family history of a single-gene condition - if a genetic parent or egg donor is a known carrier of a serious inherited condition, PGT-M may be the relevant conversation rather than PGT-A.
Balanced translocation or inversion in a genetic parent - a known structural rearrangement often points toward PGT-SR so the lab can screen for unbalanced embryos.
Number of embryos created - PGT is most useful when there are multiple blastocysts to screen, because the information helps prioritize which to transfer. With very few embryos, the conversation shifts toward whether testing reduces options.
History of repeated unsuccessful transfers or pregnancy loss - some intended parents explore PGT-A after prior implantation failure or loss, to help select embryos with the expected chromosome count. This is a decision to make with your physician based on your specific history.
Desire to limit the number of transfer attempts - because a screened euploid embryo is associated with a higher expected implantation rate per transfer in many cases, some families use PGT to reduce the number of transfers needed. This is a trade-off conversation, not a certainty.
Single-embryo transfer goals - many clinics favor single-embryo transfer for safety. PGT can support that goal by helping identify the single best embryo to transfer, which matters for both the surrogate's safety and the health of the resulting pregnancy.
Cost and timeline tolerance - PGT adds a laboratory step, a waiting period for results, and a separate line of cost. Families weigh that against the potential to avoid a transfer of an embryo unlikely to succeed. The broader journey budget is outlined in our cost breakdown.

Illustrative Scenarios (Examples Only - Not Quotes or Estimates)

The following three scenarios are fictional, simplified illustrations created to show how PGT conversations commonly differ. They are not quotes, not estimates, not predictions, and not representations of any real person, clinic, agency, or outcome. Your situation will be different, and only your own physician and reproductive attorney can advise you.

Scenario A - a known single-gene condition. A intended father is a known carrier of a serious autosomal recessive condition. The couple's physician recommends PGT-M rather than PGT-A, because the central question is whether each embryo inherited the variant, not simply the chromosome count. A custom probe is built for that specific gene. This scenario illustrates why "which PGT type" depends on family history rather than a one-size approach.

Scenario B - egg source age and multiple blastocysts. An intended parent using donated eggs at a younger age produces several blastocysts. The clinic discusses PGT-A as optional, noting that aneuploidy risk is generally lower with younger egg sources, but that screening may still help prioritize which embryo to transfer first. This scenario illustrates how the same test can be framed differently depending on the egg source's age.

Scenario C - prior loss and limited embryos. A couple with a history of early pregnancy loss creates two blastocysts. Their physician discusses whether biopsy of both is advisable given the small number, and whether a fresh transfer without testing might be considered. This scenario illustrates the trade-off conversation that arises when embryo count is low, and why PGT is not automatically the default.

None of these scenarios implies a success rate, a price, a clinic recommendation, or a legal conclusion. They are teaching examples only.

U.S. State and Jurisdiction Differences

A common misconception is that PGT itself is regulated differently state by state. In practice, the genetic testing of embryos is performed by accredited laboratories and is available across the United States. The more important jurisdiction differences for intended parents are the ones that surround the surrogacy journey as a whole.

Surrogacy legality and enforceability - where you can legally and safely pursue gestational surrogacy varies significantly by state. Some states have clear, supportive statutory frameworks; others are restrictive or silent. Because PGT only matters if you have a place to transfer the screened embryo, the state's surrogacy posture shapes the entire plan. Our international surrogacy guide and legal process guide explain why jurisdiction selection is a foundational decision.
Parentage and pre-birth orders - how and when intended parents are recognized as legal parents differs by state and affects how the journey is structured around the transfer and birth.
Insurance and mandate differences - whether any portion of IVF, medication, or genetic testing is covered by insurance depends heavily on state insurance mandates and the specific plan. This affects out-of-pocket planning documented in our financing overview.
Genetic privacy and testing consent - a small number of states have specific laws touching genetic testing, consent, and the handling of genetic information. These are nuanced and are exactly why intended parents should review the plan with a reproductive attorney in the relevant jurisdiction.
Residency and agency rules - some agencies and clinics operate only in certain states, which can influence where the medical portion of the journey is completed even if the surrogate lives elsewhere.

The practical rule: PGT is broadly available, but the journey around it is jurisdiction-sensitive. The state you choose for surrogacy - not the test itself - is usually the bigger variable, and that choice should be made with qualified legal counsel.

Cost and Timeline Anchors (Industry Reference Only)

The single most important financial framing for intended parents is that PGT is one line item inside a much larger journey. The figures below are broad industry-reference ranges for a complete U.S. gestational surrogacy journey that may include IVF and screening, compiled from commonly cited program structures. They are not a quote, not an offer, and not a guarantee from any clinic, agency, or attorney, and actual costs vary widely by program, geography, medical needs, and legal complexity.

Item	Industry-reference anchor	Notes
Full U.S. gestational surrogacy journey (all-in reference)	$140,000 - $200,000+	Commonly cited all-in range when IVF, screening, agency, legal, surrogate compensation, and insurance are included; many journeys fall outside this band.
Medical stage duration	2 - 4 months	Covers stimulation, retrieval, blastocyst culture, biopsy, genetics-lab turnaround, and the first transfer preparation.
Total journey duration	12 - 24 months	From agency/surrogate matching through birth, including screening, legal contracts, and pregnancy.
PGT as a component	Billed separately, varies by lab, panel, and embryo count	Discussed as its own line item with your clinic and lab; not a fixed figure.
Frozen embryo storage	Recurring separate fee	Usually billed per year and independent of the testing itself.

For a detailed, component-by-component view of the larger budget, see our surrogacy cost breakdown and our cost and financing resource. Our timeline guide expands on the month-by-month sequence.

Practical Checklist Before You Decide on PGT

Use this checklist as a conversation aid with your clinic and attorney - not as a decision on its own:

Review both genetic parents' carrier screening and family history with a physician or genetic counselor.
Confirm which PGT type (A, M, or SR) is relevant to your history, if any.
Ask your clinic how biopsy and vitrification are performed and what their blastocyst rates look like.
Ask which accredited genetics laboratory processes the samples and what the typical turnaround is.
Clarify exactly what is billed as "PGT" versus IVF, freezing, storage, and transfer.
Discuss single-embryo transfer policy and how PGT results inform transfer order.
Confirm the state or jurisdiction where the transfer will occur and how its laws affect the plan.
Review the full journey budget, including the financing options available to you.
Document your questions and the answers you receive from licensed professionals.

Frequently Asked Questions

Is PGT required for surrogacy?
No. Preimplantation genetic testing is an optional step. Some intended parents and clinics choose it; others proceed without it based on medical history, embryo count, cost, and personal preference. The decision should be made with your physician and reproductive attorney, not assumed.

What is the difference between PGT-A, PGT-M, and PGT-SR?
PGT-A screens for the expected number of chromosomes, PGT-M tests for a specific inherited single-gene condition when there is a known carrier or affected parent, and PGT-SR is used when a genetic parent has a balanced chromosomal translocation or inversion. They answer different questions and are not interchangeable.

Does PGT guarantee a healthy baby?
No test can guarantee a healthy pregnancy or child. PGT reduces the chance of transferring an embryo with certain detectable chromosomal or single-gene issues, but it does not screen for every condition, and it cannot eliminate all pregnancy or health risks. Prenatal care and screening remain part of the journey.

How long does it take to get PGT results?
For PGT-A, results commonly return within one to two weeks after the biopsy samples reach the genetics laboratory, though timelines vary by lab and volume. PGT-M and PGT-SR often take longer because a custom probe may need to be built for the specific condition before testing begins.

Are the embryos damaged by the biopsy?
Biopsy is performed by trained embryologists on blastocyst-stage embryos, sampling trophectoderm cells (placental-lineage tissue) rather than the inner cell mass. As with any laboratory procedure, there are risks, and the specifics should be discussed with your clinic. This article does not make any safety claim.

Can PGT tell me the sex of the embryo?
Because PGT-A evaluates chromosomes, including the sex chromosomes, the test can reveal sex as a byproduct. Whether and how sex selection is permitted or discussed depends on the laws of your jurisdiction and the policies of your clinic; this is a legal and ethical question to raise with your reproductive attorney.

Is PGT covered by insurance?
Coverage varies enormously by state insurance mandate, employer plan, and policy language. Some plans cover parts of IVF but not genetic testing; others cover neither. Confirm coverage directly with your insurer and review our financing overview for planning context.

Does PGT improve the chance that the first transfer works?
Many clinics report that transferring a screened euploid embryo is associated with a higher expected implantation rate per transfer compared with untested embryos, which can reduce the number of transfers needed. This is a statistical association, not a personal guarantee, and the trade-offs should be weighed with your physician. We cover related outcome factors in our success factors guide.

What happens to embryos that test aneuploid or affected?
Disposition of embryos that do not meet the criteria for transfer is a deeply personal and legally governed decision. Options and restrictions vary by state and clinic, and the plan should be documented with your reproductive attorney and clinic before the cycle.

Should international intended parents worry about PGT availability in the U.S.?
PGT is widely available through U.S. accredited genetics laboratories, so availability is generally not the constraint. The larger considerations for families abroad are the U.S. surrogacy jurisdiction, travel, legal parentage, and overall budget, which our international guide addresses in detail.

A Note on ASRM and SART

The American Society for Reproductive Medicine (ASRM) publishes practice guidance and committee opinions that inform how U.S. clinics approach embryo biopsy, genetic testing, and the use of PGT. The Society for Assisted Reproductive Technology (SART) collects and reports clinic-level data on assisted reproductive cycles, which intended parents can review when evaluating programs. These organizations provide professional standards and aggregated data, not personalized medical advice. Intended parents should rely on their own physician, genetic counselor, and reproductive attorney - and on the specific consent forms of the clinic and laboratory they choose - rather than on general organizational guidance alone.

Practical Next Steps

If you are considering PGT as part of a surrogacy journey, a sensible sequence is:

Start with the medical basics - read our how IVF and surrogacy work and understanding gestational surrogacy guides to place testing in context.
Gather family history - collect both genetic parents' carrier-screening results and any known conditions before speaking with a clinic.
Consult a reproductive attorney early - jurisdiction choice drives much of the plan; our legal process guide explains the contract stage.
Interview clinics and agencies - use our agency selection guide to compare how programs handle screening, transparency, and communication.
Plan the budget - review our cost breakdown and financing resource so the PGT line item sits inside a realistic total.
Prepare emotionally - the waiting and uncertainty are real; our emotional preparation guide offers perspective for intended parents.

You can also explore becoming a parent through our program pages for intended parents working with a surrogate and for those considering egg donation.

Medical and Legal Disclaimer

This article is provided for general informational and educational purposes only by Dreams of Parenthood. It does not constitute medical, genetic, psychological, legal, or tax advice, and it is not a quote, offer, guarantee, or prediction of any outcome, cost, timeline, test result, or success rate. All medical decisions - including whether to pursue PGT-A, PGT-M, PGT-SR, or no testing at all - must be made with a licensed physician, genetic counselor, and accredited laboratory, based on your individual history and the specific consent forms of your chosen clinic. All legal decisions, including jurisdiction selection, parentage, and embryo disposition, must be made with a qualified reproductive attorney in the relevant state or country. Preimplantation genetic testing carries limitations, including but not limited to the possibility of mosaicism, inconclusive results, and the inability to detect all genetic or health conditions. No statement here should be relied upon as a substitute for professional counsel. Nothing in this article creates an attorney-client or physician-patient relationship with Dreams of Parenthood.

PGT and Embryo Screening in Surrogacy: What Intended Parents Should Know